Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1382581 | 1.00 | GCK (1.00) | GCK | |
| SCHEMBL2463643 | 1.00 | GCK (1.00) | GCK | |
| Hydrochloric Acid SCHEMBL2460766 | 0.99 | GCK (0.98) | GCK | |
| SCHEMBL1381285 | 0.95 | GCK (0.90) | GCK | |
| SCHEMBL1381028 | 0.94 | GCK (0.89) | GCK | |
| SCHEMBL1382392 | 0.94 | GCK (0.88) | GCK | |
| SCHEMBL1379076 | 0.93 | GCK (0.87) | GCK | |
| SCHEMBL1381255 | 0.93 | GCK (0.86) | GCK | |
| SCHEMBL2655793 | 0.93 | GCK (0.86) | GCK | |
| SCHEMBL1380461 | 0.93 | GCK (0.86) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735322-B1 | SULFONAMIDE-THIAZOLPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS USEFUL FOR THE TREATMENT OF TYPE 2 DIABETES | NOVARTIS AG (CH) | 2011-09-14 | — | — | EP | disclosed |
| US-7750020-B2 | 3-Cyclopentyl-2-(4-cyclopropylsulfamoyl-phenyl)-N-(5-methoxy-thiazolo[5,4-b]pyridin-2-yl)-propionamide; antidiabetic agent; insulin resistance, impaired glucose tolerance, obesity; with other hypolipidemic agent, anti-obesity and hypotensive agent | NOVARTIS AG (CH) | 2010-07-06 | — | — | US | disclosed |
| US-7750020-B2 | 3-Cyclopentyl-2-(4-cyclopropylsulfamoyl-phenyl)-N-(5-methoxy-thiazolo[5,4-b]pyridin-2-yl)-propionamide; antidiabetic agent; insulin resistance, impaired glucose tolerance, obesity; with other hypolipidemic agent, anti-obesity and hypotensive agent | NOVARTIS AG (CH) | 2010-07-06 | — | — | US | disclosed |
| US-7750020-B2 | 3-Cyclopentyl-2-(4-cyclopropylsulfamoyl-phenyl)-N-(5-methoxy-thiazolo[5,4-b]pyridin-2-yl)-propionamide; antidiabetic agent; insulin resistance, impaired glucose tolerance, obesity; with other hypolipidemic agent, anti-obesity and hypotensive agent | NOVARTIS AG (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20080103167-A1 | Sulfonamide-Thiazolpyridine Derivatives As Glucokinase Activators Useful The Treatment Of Type 2 Diabetes | NOVARTIS AG (CH) | 2008-05-01 | — | — | US | disclosed |
| US-20080103167-A1 | Sulfonamide-Thiazolpyridine Derivatives As Glucokinase Activators Useful The Treatment Of Type 2 Diabetes | NOVARTIS AG (CH) | 2008-05-01 | — | — | US | disclosed |
| US-20080103167-A1 | Sulfonamide-Thiazolpyridine Derivatives As Glucokinase Activators Useful The Treatment Of Type 2 Diabetes | NOVARTIS AG (CH) | 2008-05-01 | — | — | US | disclosed |
| WO-2005095418-A1 | SULFONAMIDE-THIAZOLPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS USEFUL THE TREATMENT OF TYPE 2 DIABETES | NOVARTIS AG (CH) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103167-A1 | Sulfonamide-Thiazolpyridine Derivatives As Glucokinase Activators Useful The Treatment Of Type 2 Diabetes | GCKR, GCK, SLC5A2 | GCK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.